title: Current perspectives on HIV-1 antiretroviral drug resistance.
abstract: Current advancements in antiretroviral therapy (ART) have turned HIV-1 infection into a chronic and manageable disease. However, treatment is only effective until HIV-1 develops resistance against the administered drugs. The most recent antiretroviral drugs have become superior at delaying the evolution of acquired drug resistance. In this review, the viral fitness and its correlation to HIV-1 mutation rates and drug resistance are discussed while emphasizing the concept of lethal mutagenesis as an alternative therapy. The development of resistance to the different classes of approved drugs and the importance of monitoring antiretroviral drug resistance are also summarized briefly.
authors.affiliation: Department of Pharmacology, School of Medicine, Yale University, New Haven, CT 06520, USA. pinar.iyidogan@yale.edu.
authors.forename: Pinar
authors.initials: P
authors.lastname: Iyidogan
authors.affiliation: Department of Pharmacology, School of Medicine, Yale University, New Haven, CT 06520, USA. karen.anderson@yale.edu.
authors.forename: Karen S
authors.initials: KS
authors.lastname: Anderson
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology; D044966:Anti-Retroviral Agents / Q000494:pharmacology*; D024882:Drug Resistance, Viral / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics* / Q000502:physiology; D006801:Humans; D016296:Mutagenesis
chemical_list: D019380:Anti-HIV Agents; D044966:Anti-Retroviral Agents